MKI67 and neoplasm: Histopathological and proliferation analysis using hematoxylin & eosin (H&E) and Ki‐67 staining confirmed the significant antitumor effects of ZAK‐I‐57 in PLC/PRF/5 tumor‐bearing and PDTX mouse model tissues, indicating its potential as a superior therapeutic agent compared to sorafenib, as shown in Figure 6A–F.